Advanced searches left 3/3

Carcinoma Esophagus - Europe PMC

Summarized by Plex Scholar
Last Updated: 19 November 2022

* If you want to update the article please login/register

Reply to Letter to the Editor regarding "Oncological outcomes of squamous cell carcinoma of the cervical esophagus treated with definitive (chemo-)radiotherapy: a systematic review and meta-analysis".

We performed a meta-analysis of the oncological findings of patients with cervical esophageal squamous cell carcinoma treated with definitive chemoradiotherapy in a previous research. An increased RT dose may not be related to an elevated OS, according to the included studies, the median radiotherapy dose of 61. 2 Gy was found by a non-significant effect of the pooled overall survival.

Source link: https://europepmc.org/article/MED/36309603


High Serum Squamous Cell Carcinoma Antigen Level Associated with Remission of Mild/Moderate Dysplasia of the Esophagus: A Nested Case-Control Study.

This research sought to determine the correlation between the serum squamous cell carcinoma antigen and esophageal squamous mild to moderate dysplasia. During the years of 2013-2015, patients with mild/moderate dysplasia of the esophageal squamous epithelium were included in this research, which culminated in a follow-up endoscopy during 2017-2018. To determine the diagnostic efficiency of the regression status of dysplasia under the predictive model, a receiver operating characteristic curve was used. A failure or stable diagnosis of dysplasia was seen in 100 patients, and 46 patients had a progressed status. The area under the ROC curve was 0. 78 percent in the predictive model. Conclusions: Increased serum SCCA concentrations was correlated with decreased severity of mild and moderate dysplasia of the esophageal mucosa. Further research was warranted, and the SCCA concentration was a potential biomarker for dysplasia prognosis.

Source link: https://europepmc.org/article/MED/36275424


Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy.

For improving disease prevention, a better understanding of the molecular heterogeneity and tumor immune microenvironment in ESCC is required. Methods based on the DNA methylation and gene expression profiles of ESCC patients, we can identify molecular subtypes of patients and create a predictive model for subtype classification based on their data. In an independent validation cohort of Chinese ESCC patients receiving immunotherapy, the clinical value of molecular subtypes for the prediction of immunotherapy effectiveness is assessed. According to S2 subtype patients, they had a poorer prognosis. The response rate of immunotherapy in the S1 subtype is noticeably higher than in the S2 subtype patients.

Source link: https://europepmc.org/article/MED/36291754


Factors associated with pathologic complete response following neoadjuvant chemoradiation and esophagectomy for carcinoma of esophagus and gastroesophageal junction.

Patients with EC and GEJ tumors who underwent esophagectomy from January 2010 to March 2021 were included. Univariate and multivariate analyses were used to determine the risk factors associated with pCR by comparing the patients who achieved pCR with those who did not achieve pCR. Patients in the pCR group had significantly improved overall and disease-free survival in comparison to patients in the non-pCR group. PCR was correlated with improved prognosis in patients with tumors of EC and GEJ who underwent esophagectomy, compared to those without achieving pCR.

Source link: https://europepmc.org/article/MED/36129433


Limited-stage small cell carcinoma of the esophagus treated with curative esophagectomy: A multicenter retrospective cohort study.

Background This research was designed to investigate the safety of surgery in the treatment of small cell carcinoma of the esophagus, as well as potential prognostic factors. Methods We screened patients with SCCE who underwent esophagectomy at three hospitals from 2010 to 2018. Stage IB and stage IIB disease were mixed with the surgery response syndrome, while stage III disease was converted into the surgery nonresponse disease. Compared to the SNRD group, the SRD group had a significant rise in survival. In addition, adjuvant therapy improved survival in the SNRD group but not in the SRD group.

Source link: https://europepmc.org/article/MED/36036894

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions